Skip to main content

Web Exclusives

FDA Approvals
Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer
Read More
FDA Approvals
FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma
Read More
FDA Approvals, Urothelial Cancer, Oncology
Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer
Read More
In the News, Practice Management
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Read More
FDA Approvals
Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma
Read More
In the Literature, Oncology
Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes
Read More
FDA Approvals, In the News
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Read More
FDA Approvals, In the News
Mixed Findings in Annual Cancer Statistics Report
Read More
FDA Approvals, In the News
FDA Grants Approval to Avapritinib for Patients with GIST
Read More
Perspectives
Paying Tribute to Geno J. Merli, MD, MACP
David B. Nash, MD, MBA
Read More
Page 17 of 37
Results 161 - 170 of 366